3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Sarcoma
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Multiple Primary
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Locally Advanced Rectal Carcinoma
1
Histiocytoma, Malignant Fibrous
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Advanced Pancreatic Cancer
1
Interventions
Oxaliplatin
47
Capecitabine
46
Fluorouracil
40
Leucovorin
30
Radiotherapy
25
Irinotecan
20
Chemoradiotherapy
14
Bevacizumab
14
Cetuximab
12
Neoadjuvant Therapy
11
Folfox protocol
11
Chemotherapy, Adjuvant
11
XELOX
10
Laparoscopy
10
Drug Therapy
9
Surgical Procedures, Operative
6
Robotic Surgical Procedures
5
Radiation
5
Mastectomy, Segmental
5
Surveys and Questionnaires
4
Radiotherapy, Intensity-Modulated
4
Panitumumab
4
Gemcitabine
4
FOLFOXIRI protocol
4
durvalumab
3
Simvastatin
3
Magnetic Resonance Spectroscopy
3
Indocyanine Green
3
tislelizumab
2
regorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Rectal Neoplasms
×
envafolimab
×
Clear all
NCT05858567
2023-05-15
RECMULRA-TNT
Sir Run Run Shaw Hospital
Phase 2
Unknown
30 enrolled